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Obesity-related adipose tissue (AT) inflammation that promotes metabolic dysregulation 
is associated with increased AT mast cell numbers. Mast cells are potent inducers of 
inflammatory responses and could potentially contribute to obesity-induced AT inflam-
mation and metabolic dysregulation. Conflicting findings were reported on obesity- 
related metabolic dysfunction in mast cell-deficient mice, thus creating a controversy that 
has not been resolved to date. Whereas traditional Kit hypomorphic mast cell-deficient 
strains featured reduced diet-induced obesity and diabetes, a Kit-independent model of 
mast cell deficiency, Cpa3Cre/+ mice, displayed no alterations in obesity and insulin sensi-
tivity. Herein, we analyzed diet-induced obesity in Mcpt5-Cre R-DTA mice, in which the 
lack of mast cells is caused by a principle different from mast cell deficiency in Cpa3Cre/+ 
mice or Kit mutations. We observed no difference between mast cell-deficient and 
-proficient mice in diet-induced obesity with regards to weight gain, glucose tolerance, 
insulin resistance, metabolic parameters, hepatic steatosis, and AT or liver inflammation. 
We conclude that mast cells play no essential role in obesity and related pathologies.
Keywords: mast cell deficiency, diet-induced obesity, metabolic dysregulation, insulin resistance, glucose 
tolerance
inTrODUcTiOn
Inflammation has emerged as an important player in the pathogenesis of obesity-associated meta-
bolic dysfunction and the development of insulin resistance and type 2 diabetes (1–3). In the course 
of obesity, inflammatory cells, including macrophages (Mφs) and lymphocytes, accumulate in the 
adipose tissue (AT) and the liver (3, 4). A switch toward the pro-inflammatory (M1) state of Mφs 
and increased levels of pro-inflammatory mediators, such as TNF, in the obese AT substantially 
contribute to insulin resistance of adipocytes (1, 5). Therefore, identifying the exact mechanisms and 
cellular and molecular players governing this immune–adipose crosstalk in obesity is of particular 
importance.
Mast cells are tissue-resident hematopoietic cells that potently induce inflammatory responses 
upon ligation of their surface IgE (6). Release of pro-inflammatory mediators by mast cells can be 
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also triggered via different pattern recognition receptors on mast 
cells (7). Therefore, different pro-inflammatory actions ascribed 
to mast cells in the context of homeostatic or pathogenic immu-
nity that derived from experiments with Kit hypomorphic mast 
cell-deficient mouse strains over the past two decades appeared 
very plausible (8–10). However, several key findings in Kit mutant 
mast cell-deficient models were not reproduced in novel mouse 
strains, in which mast cell deficiency was based on principles 
that were distinct from compromised Kit expression. This has led 
to the assumption that several of the broad actions attributed to 
mast cells resulting from experiments with Kit mutant mast cell-
deficient mice may be actually due to disrupted Kit function and 
the complex alterations of the immune system in these strains, 
rather than mast cell deficiency itself (11). Therefore, the roles 
mast cells play in the immune system and different pathologies 
are still unclear.
Few mast cells are found in healthy AT. However, their 
numbers increase in obesity-related AT inflammation (12–15), 
which has led to the obvious question whether these cells con-
tribute to obesity-related metabolic dysregulation. Kit mutant 
mast cell-deficient mice of the KitW/W-v and the KitW-sh/W-sh strains 
feature improved metabolic parameters upon hypercaloric 
challenge, including improved insulin sensitivity and glucose 
tolerance (12). These data raised hopes that metabolic disease 
might be amenable to therapy targeting mast cells. However, the 
protection from metabolic dysregulation characterizing the Kit 
hypomorphic mast cell-deficient mouse strains was not observed 
in a recent study using the novel Cpa3Cre/+ mouse line that lacks 
mast cells, but expresses normal levels of functional Kit (16). In 
the latter model, in which all mast cells are deleted by genotoxic 
effects of Cre recombinase expressed at high levels under the 
control of the carboxypeptidase A promoter (11, 17), no effect 
of mast cell-deficiency on obesity-associated weight gain, insulin 
resistance, and AT inflammation was observed (16). The same 
article demonstrated that the absence of Kit itself protected from 
obesity (16). The controversy was fueled by a recent study based 
on experiments in KitW-sh/W-sh mice, proposing that leptin may 
regulate the inflammatory phenotype of mast cells, which in turn 
modulate obesity-related AT inflammation (18).
These controversial findings prompted us to analyze, here, 
diet-induced obesity in a third independent mouse model of mast 
cell deficiency, in which the absence of mast cells is caused by a 
principle different from Kit hypomorphic alleles and also from 
the genotoxic loss of mast cells in Cpa3Cre/+ mice (19, 20). The 
purpose of our study was, therefore, to shed more light onto the 
controversy regarding the role of mast cells in the development 
of obesity and related metabolic dysregulation. Our findings 
unequivocally demonstrate that mast cells do not contribute to 
obesity-related inflammation and metabolic dysregulation.
MaTerials anD MeThODs
animals
The Mcpt5-Cre+R-DTA+ mouse line was established as described 
previously (20). Mast cell-deficient (Mcpt5-Cre+R-DTA+, n = 8) 
and -proficient (Cre-negative R-DTA+, n =  10) littermate male 
mice were subjected to a high-fat diet (HFD, 60% calories from 
fat) (Research Diets, New Brunswick, NJ, USA) for a time period 
of 21 weeks. Body weight was recorded on a weekly basis. At week 
10 of the HFD feeding, metabolic performance was measured 
in a subgroup of mice using comprehensive laboratory animal 
monitoring system (CLAMS). Mice were placed in metabolic 
cages (PhenoMaster; TSE Systems, Bad Homburg, Germany) 
with free access to water and food and 12/12  h light/dark 
cycle for three consecutive days and nights. Volume of oxygen 
consumption (VO2) and carbon dioxide production (VCO2) 
were determined automatically every 20  min as well as water 
consumption and food intake. The respiratory exchange ratio 
(RER) was calculated as VCO2/VO2. Motility was recorded by an 
infrared sensor and measured every 20 min as number of events 
per period (20 min); averages were calculated for day and night 
periods. Data were normalized with respect to body weight using 
analysis of covariance (ANCOVA). Cholesterol and triglycerides 
levels were measured in blood after 16  h of starvation with 
AccuTrend (Roche, Mannheim, Germany). Glucose tolerance 
test (GTT) and insulin tolerance test (ITT) were performed as 
previously described (21, 22). GTT was performed after 16 h of 
starvation after 18 weeks on HFD by injecting glucose (1 g/kg of 
bodyweight) i.p. and by measuring glucose in blood with glucom-
eter (Accu-Chek, Roche, Mannheim, Germany) at different time 
points, as shown in the figures. ITT was performed after 6 h of 
starvation after 19–20 weeks on HFD by injecting insulin 1.5 IU/
kg of bodyweight i.p. and glucose was measured at different time 
points, as shown in the figures. After euthanizing mice, sera, 
subcutaneous and gonadal AT (sAT and gAT), liver, pancreas, 
and muscle (quadriceps) were collected and used either directly 
or stored at −80°C for further analysis. Animal experiments were 
approved by the Landesdirektion Sachsen, Germany.
analysis of aT inflammation
Stromal vascular fraction (SVF) was isolated as described previ-
ously (23, 24). Briefly, sAT and gAT were isolated and immediately 
minced and digested with type I collagenase (Gibco, Darmstadt, 
Germany). Digested AT was filtered through 100 μm cell strainer 
(BD, Heidelberg, Germany), and the adipocyte fraction was 
removed by centrifugation. SVF cells in the pellet were washed 
and resuspended in FACS buffer (PBS, 0.1%BSA, 0.1%NaN3) and 
analyzed for the content of inflammatory and immune cells by 
using flow cytometry (FACS Canto II, BD Bioscience). Mφs were 
detected as CD11b+ F4/80+; M1 Mφs were detected as CD11b+ 
F4/80+ CD11c+ cells. Total T cells (CD3+) were further divided 
into T helper (CD3+ CD4+) and cytotoxic T cells (CD3+ CD8+). 
Fc receptors on leukocytes were blocked by anti-CD16/CD32 
antibody (BD, Heidelberg, Germany). The following fluores-
cently labeled antibodies were used: CD11b-APC, CD11c-PE 
(BD, Heidelberg, Germany), F4/80-Alexa-fluor 488 (eBiosci-
ence, Frankfurt, Germany), CD8a-APC, CD4-FITC, CD3e-PE 
(Miltenyi Biotec GmbH, Bergisch Gladbach, Germany).
Plasma and serum analysis
Plasma was obtained from heparinized blood from mice that were 
starved for 16 h. Insulin was measured in plasma by using insulin 
immunoassay (Crystal Chem, Cologne, Germany). After killing 
FigUre 1 | Mast cell deficiency in the Kit-independent Mcpt5-Cre R-DTA model does not affect body weight, glucose tolerance, and insulin 
resistance in diet-induced obesity. (a,B) Mast cell-deficient Mcpt5-Cre+R-DTA+ and mast cell-proficient Cre-negative R-DTA+ littermate control male mice were 
fed a HFD and weight (a) and weight gain (B) were recorded. (c,D) Glucose tolerance test (c) and insulin tolerance test (D) were performed in mast cell-deficient 
Mcpt5-Cre+R-DTA+ and mast cell-proficient Cre-negative R-DTA+ littermate mice subjected to diet-induced obesity. In (D), data are presented as percentage of initial 
glucose level. Data and corresponding area under curve (AUC) analysis are shown. AUC data are presented as % of control; the Cre-negative group was set as the 
100% control. AUC data were tested for statistical significance with Student’s t-test. Data are expressed as means ± SEM (n = 8–10 mice).
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mice, the serum was collected and analyzed for adiponectin by 
using an immunoassay (R&D Systems, Wiesbaden-Nordenstadt, 
Germany).
Quantitative real-Time Pcr
Total RNA was isolated from AT and liver by using phenol/chlo-
rophorm extraction (TRI Reagent, MRC, Cincinnati, OH, USA). 
The expression of inflammatory (IL-1β, IL-6, IL-10, TNF, MCP-1, 
and F4/80) and metabolic (PPARγ, Srebp1c, LPK, GK, G6P, FATP2, 
CD36, MTTP and Glut-2) genes (for detailed description see Mast 
Cell Deficiency Does Not Affect Obesity-Related Liver Steatosis 
and Inflammation section in Results) was analyzed using SsoFast 
EvaGreen Supermix (BioRad) on real-time PCR cycler CFX384 
(BioRad, Munich, Germany). The expression was normalized to 
Cre- (mast cell proficient) group by using 18S RNA as a reference 
and quantified with ΔΔCt method (25). Primers used in the 
study: mTNF-a_F – AGCCCCCAGTCTGTATCCTTCT, mTNF-
a_R – AAGCCCATTTGAGTCCTTGATG, mIL-10_F – TAAGG 
CTGGCCACACTTGAGA, mIL-10_R – AGCTGCTGCAGGAAT 
GATCA, mF4/80_F  –  TCAAGGCCATTGCCCAGAT, mF4/ 
80_R – TCCCGTACCTGACGGTTGAG, mIL-1β_F – ATCCC 
AAGCAATACCCAAAG, mIL-1β_R – GTGCTGATGTACCAGT 
TGGG, mMCP-1_F – GCATCTGCCCTAAGGTCTTC, mMCP- 
1_R – AAGTGCTTGAGGTGGTTGTG, mPPARg_F – GAGTGT 
GACGACAAGATTTG, mPPARg_R – GGTGGGCCAGAATG 
GCATCT, Srebp1c_F  –  GATCAAAGAGGAGCCAGTGC, 
Srebp1c_R – TAGATGGTGGCTGCTGAGTG, mGK_F – TGC 
GGAGATGCTCTTTGACT, mGK_R – TCTCGGAGAAG 
TCCCACGAT, mLPK_F – CTTGCTCTACCGTGAGCCTC, 
mLPK_R – ACCACAATCACCAGATCACC, mG6Pase_F – TGG 
AGTCTTGTCAGGCATTG, mG6Pase_R – TCCAAAGTCCA 
CAGGAGGTC, mFATP2_F – CTACGCATCCACTGAAGGCA, 
mFATP2_R – AGTCCAACCTCACCTTTGGG, mCD36_F – 
AGGTCTATCTACGCTGTGTTC, mCD36_R – ATGGTTGTCT 
GGATTCTGGAG, Mttp_F – CACTCAGGCAATTCGAGACA, 
Mttp_R – TCTGGCTGAGGTGGGAATAC, mGlut2_F – ATTC 
GCCTGGATGAGTTACG, mGlut2_R – CCAGCGAAGAGGA 
AGAACAC, m18S rRNA_F – GTTCCGACCATAAACGATGCC, 
and m18S rRNA_R – TGGTGGTGCCCTTCCGTCAAT.
histology and histochemistry
Paraffin stocks were prepared from gAT and liver, 5 μm thick 
cuts were transferred onto slides and were stained with Mayer’s 
hematoxylin (SAV, Flintsbach a. Inn, Germany) and counter-
stained with 1% eosin (Seipt, Germany) for the analysis of 
adipocyte size and liver steatosis. Mast cell accumulation in 
gAT was detected by using Giemsa staining (Sigma-Aldrich, 
Munich, Germany). Steatosis, lobular inflammation, and 
hepatocellular ballooning were evaluated according to previ-
ously published criteria, following the NASH-CRN Committee 
scoring system (26). Steatosis and inflammation were scored 
using a 0–3 scale, ballooning by using a 0–2 scale. The NAFLD 
activity score (NAS) was defined as the sum of steatosis, 
lobular inflammation, and ballooning, thus ranging from 0 
to 8. A microscope coupled to a computerized system (Zeiss, 
Oberkochen, Germany) and equipped with the AxioVision Rel. 
4.8 software (Carl-Zeiss MicroImaging GmbH, Jena, Germany) 
was used.
FigUre 2 | no metabolic differences between obese mast cell-deficient and -proficient mice. (a) After 21 weeks on HFD, mice were euthanized and 
dissected. Tissues were collected, and their weights were recorded. sAT, subcutaneous AT; gAT, gonadal AT. (B,c) Levels of cholesterol and triglycerides in blood 
were measured after 16 h of starvation in obese mast cell-deficient and -proficient mice. (D) Insulin in the plasma from obese mast cell-deficient and -proficient mice 
was measured after 16 h of starvation. (e) Adiponectin in serum from obese mast cell-deficient and -proficient mice was measured. (F–J) Metabolic performance of 
obese mast cell-deficient and -proficient mice was analyzed by using comprehensive laboratory animal monitoring system (CLAMS) for three consecutive days and 
nights. (F) Respiratory exchange ratio (RER); data are shown as area under curve (AUC) of the experimental period (3 days and 3 nights together). AUC data are 
presented as % of control; the Cre-negative group was set as the 100% control. (g) Calories consumption; data are shown as area under curve (AUC) of the 
experimental period (3 days and 3 nights together). AUC data are presented as % of control; the Cre-negative group was set as the 100% control. (h) Cumulative 
water consumption at the end of the experimental period (3 days). (i) Cumulative food intake at the end of the experimental period (3 days). (J) Mouse motility 
(events/20 min) during light and dark period of the three consecutive days and nights was measured by recording motion events with infrared motion sensor. (K) 
Morphology of the gonadal AT from obese mast cell-deficient and -proficient mice was performed with hematoxylin/eosin staining; representative images are shown. 
Student’s t-test (a–e) and ANCOVA (F–J) with animal body weight as covariant were used for statistical evaluation, n = 8–10 mice [in (a–e)] and n = 4 mice/group 
[in (F–J)]. Data are expressed as means ± SEM.
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statistical analysis
Student’s t-test was used for statistical analysis of most experi-
ments, non-parametrical Mann–Whitney U test was used for 
quantitative Real-Time PCR (qPCR) evaluation and ANCOVA, 
with respect to mouse bodyweight, was used for analysis of data 
from metabolic cages. All data are expressed as means ± SEM; the 
level of significance was set at p < 0.05.
resUlTs
no Difference in Metabolic Parameters 
between Mast cell-Deficient  
and -Proficient Mice
Crossing of Mcpt5-Cre transgenic mice (19) to the R-DTA line 
(27) results in profound deficiency for connective tissue mast 
cells, the subset of mast cells populating most tissues, including 
AT, due to selective suicidal expression of diphtheria toxin A in 
Mcpt5-Cre+R-DTA+ animals. Lack of connective tissue mast cells 
is reflected by absence of IgE-mediated anaphylaxis, whereas 
the numbers of other major immune cell types are not affected 
(28). We assessed the involvement of mast cells in diet-induced 
obesity-related metabolic dysregulation. First, a group of mast 
cell-deficient and mast cell-proficient littermate control mice was 
followed on standard diet for >15 weeks. Under these conditions, 
mast cell-deficient mice displayed no differences with regards to 
body weight, AT and liver weight, glucose tolerance, and further 
metabolic parameters, e.g., blood cholesterol, blood triglycerides, 
or blood insulin, as compared to controls (data not shown). We, 
then, performed a detailed analysis of mice in the course of HFD-
induced obesity. In contrast to KitW-sh/W-sh mice (12), but similarly 
to the Cpa3Cre+ mice (16), Mcpt5-Cre+R-DTA+ mast cell-deficient 
FigUre 3 | no difference in aT inflammation between obese mast cell-deficient and -proficient mice. (a–h) The stromal vascular fraction (SVF) of 
subcutaneous (sAT) and gonadal (gAT) adipose tissue from obese mast cell-deficient and -proficient mice was analyzed by flow cytometry for the accumulation of 
total macrophages (Mφs) and pro-inflammatory M1-polarized macrophages. The presence of CD3+ T lymphocytes and of T helper CD4+ and cytotoxic CD8+ T cells 
was analyzed. Student’s t-test was used for statistical analysis; data are expressed as means ± SEM (n = at least 8 mice/group). (a,B) Percentual analysis of 
macrophage accumulation in the sAT (a) and gAT (B). (c,D) Number of macrophages per gram of sAT (c) and gAT (D). (e,F) Percentual evaluation of T cell 
accumulation in the sAT (e) and gAT (F). (g,h) Number of T cells per gram of sAT (g) and gAT (h). (i,J) Representative images (Giemsa staining) for the presence of 
mast cells in the gAT of obese mast cell-deficient and -proficient mice (i). Mast cell deletion was evaluated (J); n = at least 8 mice/group. Mast cells were not 
present in the AT of Mcpt5-Cre+R-DTA+ mice. *p < 0.05. (K) Quantitative PCR analysis of inflammatory gene expression in the gAT of obese mast cell-deficient and 
-proficient mice. Data are shown relative to the mast cell-proficient mouse group; 18S RNA was used for normalization. Mann–Whitney U test was used for 
statistical analysis (n = 8 mice/group).
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and -proficient (Cre-negative R-DTA+) mice that were fed a 
HFD did not display any significant differences in body weight 
(Figure  1A), body weight gain (Figure  1B), glucose tolerance 
(Figure 1C), and insulin resistance (Figure 1D). Thus, mast cell-
deficiency does not affect systemic metabolic dysregulation and 
development of insulin resistance due to obesity. In accordance 
with the body weight data, the weights of the sAT, gAT, liver, 
muscle (quadriceps), and pancreas were not affected by mast 
cell-deficiency in diet-induced obesity (Figure 2A). Moreover, no 
differences in fasting blood cholesterol (Figure 2B) and triglycer-
ide levels (Figure 2C) or fasting plasma insulin levels (Figure 2D) 
were found between obese mast cell-deficient and -proficient 
mice. Furthermore, mast cell deficiency did not affect adiponec-
tin levels (Figure 2E). We subjected obese mast cell-deficient and 
-proficient mice to CLAMS analysis and observed no alterations 
in RER (Figure  2F), calories consumption (Figure  2G), water 
and food intake (Figures 2H,I), and motility (Figure 2J) between 
Cre-negative and Cre+ mice. Additionally, histological analysis 
of the AT did not display any differences between obese mast 
cell-deficient and -proficient mice (Figure 2K), with regards to 
AT morphology or adipocyte size. Together, mast cells are dis-
pensable in obesity-related metabolic dysregulation and insulin 
resistance development.
Mast cell Deficiency Does not affect 
Obesity-related aT inflammation
As mast cells have been previously proposed to contribute to a 
variety of immune responses (8–10) and especially to obesity-
related AT inflammation (12), we next evaluated inflammatory 
cell accumulation in the AT. Consistent with the findings in 
mast cell-deficient Cpa3Cre+ mice (16), flow cytometric analysis 
did not reveal any differences in the accumulation of total Mφs 
or pro-inflammatory M1-polarized CD11c+ Mφs in the sAT or 
the gAT between obese Mcpt5-Cre+ R-DTA+ mast cell-deficient 
and obese Cre-negative R-DTA+ control mice (Figures  3A–D). 
FigUre 4 | no difference in liver inflammation and metabolism between obese mast cell-deficient and -proficient mice. (a–e) Liver hematoxylin/
eosin-stained paraffin sections from obese mast cell-deficient and -proficient mice were analyzed histologically and evaluated for NAFLD activity score (NAS), 
consisting of steatosis, lobular inflammation, and hepatocellular ballooning; three sample images (400× power field) per animal were scored (n = 8–10 mice). 
Student’s t-test was used for statistical analysis; data are expressed as means ± SEM. (a) Representative images of the liver from obese mast cell-deficient and 
-proficient mice. (B) Liver steatosis was scored on a scale from 0 to 3. (c) Liver lobular inflammation was scored on a scale from 0 to 3. (D) Hepatocellular 
ballooning was scored on a scale from 0 to 2. (e) NAFLD activity score (NAS) represents the combination of steatosis, inflammation, and ballooning score on a scale 
from 0 to 8. (F,g) Quantitative PCR analysis from the livers of obese mast cell-deficient and -proficient mice was performed. Data are shown relative to the mast 
cell-proficient mouse group; 18S RNA was used for normalization. Non-parametric Mann–Whitney U test was used for statistical analysis; data are expressed as 
means ± SEM (n = 8–10 mice). (F) Quantitative PCR analysis of metabolic gene expression in the liver; *p < 0.05. (g) Quantitative PCR analysis of inflammatory 
gene expression in the liver.
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No difference in Mφ accumulation was observed when data 
were expressed as the percentage of SVF (Figures  3A,B) or 
when data were expressed as cell numbers per gram of tissue 
(Figures  3C,D). Similarly, mast cell deficiency did not affect 
accumulation of total T cell numbers (CD3+ cells), CD4+ T helper 
cell numbers, or CD8+ cytotoxic T cell numbers in the obese sAT 
or gAT (Figures 3E–H). Histological analysis of Giemsa-stained 
sections confirmed the virtual absence of mast cells in gAT of 
Mcpt5-Cre+R-DTA+ mice (Figures  3I,J). Quantitative PCR 
analysis of the gAT of obese mast cell-deficient and -proficient 
mice did not reveal any difference in the expression of cytokines 
IL-10, IL-1β, IL-6, and TNF and of the chemokine MCP-1 and 
thus in the inflammatory environment of the AT (Figure  3K). 
In conclusion, mast cells do not regulate AT inflammation in the 
course of diet-induced obesity.
Mast cell Deficiency Does not affect 
Obesity-related liver steatosis and 
inflammation
We also performed histological analysis of the livers of obese 
mast cell-deficient and -proficient mice. Hepatic steatosis 
(Figures 4A,B), as well as lobular inflammation (Figure 4C), 
hepatocellular ballooning (Figure  4D), and overall NAS 
(Figure 4E) did not differ between the two groups. Moreover, 
quantitative PCR did not display any differences in the 
expression of a series of factors involved in hepatic metabolism 
(Figure  4F), including lipogenesis [peroxisome proliferator-
activated receptor gamma (PPARγ), sterol regulatory element-
binding protein 1C (Srebp1c)], glycolysis [liver-type pyruvate 
kinase (LPK), glucokinase (GK)], the transport of fatty acids 
[fatty acid transport protein 2 (FATP2)], and triglycerides 
[CD36, microsomal triglyceride transfer protein (MTTP)] and 
glucose uptake by cells [glucose transporter 2 (Glut-2)], due 
to mast cell deficiency. The only significant difference between 
the two groups was in the expression of the gluconeogenic 
gene glucose-6-phosphatase (G6P, Figure  4F), which was 
slightly increased in mast cell-deficient mice, as compared 
to the control group. Further, we analyzed the inflammatory 
milieu of the liver of obese mast cell-deficient and -proficient 
mice and found no differences in the expression of F4/80 (as 
a surrogate marker for the presence of Mφs and Kupffer cells) 
or of the cytokines IL-1β, IL-6, and TNF and of the chemokine 
MCP-1 (Figure 4G). Therefore, mast cell deficiency does not 
contribute to obesity-associated hepatic steatosis and metabolic 
dysregulation.
DiscUssiOn
It was previously described that the AT of lean and obese mice 
differ substantially with regards to mast cell numbers (14, 29, 30). 
In addition, the obesity-related increase of mast cell numbers 
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is more prominent in gAT (29), thereby suggesting that mast 
cells might participate in obesity-related AT inflammation and 
metabolic dysregulation (12). The proposed effects of mast 
cells in obesity, however, were inferred from experiments in Kit 
mutant mast cell-deficient mouse strains KitW/W-v and KitW-sh/W-sh 
(12, 13, 18), which displayed significantly lower weight gain and 
an improved obesity-related metabolic and inflammatory phe-
notype as compared to control mice. This effect was attributed 
to the lack of mast cell-derived IFN-γ and IL-6 (12). However, 
Gutierrez et al. not only demonstrated that absence of mast cells 
has no effect on AT inflammation and metabolic dysregulation 
but also showed that the protection of Kit mutant mice against the 
effects of hypercaloric diet results rather from effects of reduced 
Kit expression than from mast cell deficiency (16). We used, here, 
a mast cell deficiency model that is based on a fundamentally 
different principle than that of the Cre-MASTER (CpaCre/+) mice 
employed by Gutierrez et al., however, our data clearly support 
the latter study.
In diet-induced obesity with mast cell-proficient and -deficient 
mice, we analyzed various metabolic parameters and we addressed 
also the inflammatory status of sAT, gAT, and the liver. We did not 
observe any substantial differences in obesity and obesity-related 
dysregulation due to mast cell deficiency. The only statistically 
significant difference was the slightly increased expression of the 
mRNA of the gluconeogenic factor glucose-6-phosphatase in the 
livers of mast cell-deficient mice. If anything, slightly enhanced 
expression of a gluconeogenic factor in mast cell-deficient mice 
would rather contribute to worse insulin sensitivity in these mice. 
However, as this was the only difference between the two groups 
and was not prominent (1.4-fold increase in mRNA levels), we do 
not consider it a relevant difference.
Our analysis included a series of metabolic parameters and 
metabolic tests in mast cell-deficient and -proficient mice in the 
course of obesity; our findings demonstrate that mast cells are 
dispensable in the pathogenesis of obesity and obesity-related 
metabolic dysfunction (e.g., glucose intolerance and insulin 
resistance). Furthermore, we demonstrate, here, that Mφ accu-
mulation and polarization toward the pro-inflammatory M1 
population in the obese AT is not affected by the presence or 
absence of mast cells. In agreement with Gutierrez et al. (16), we 
conclude that mast cells are also dispensable for the development 
of obesity-related AT inflammation. Further experimental studies 
should address the exact crosstalk between mast cells and other 
immune cells in the obese AT.
Of note, the discrepancy between Kit mutant mice and novel 
models of mast cell deficiency with unperturbed Kit function 
emerging in the analyses of diet-induced metabolic dysregula-
tion is an addition to the already long list of cases in which key 
findings in Kit mutant mice were not reproduced in novel mast 
cell-deficient mouse strains with normal Kit function (11, 17, 
20, 28, 31–37). Collectively, overwhelming evidence accumu-
lated over the past few years that Kit mutant mice are unreliable 
as models of mast cell deficiency even if observed phenotypes 
can be reversed by reconstitution with in  vitro-differentiated 
mast cells.
aUThOr cOnTriBUTiOns
JC designed and performed experiments, analyzed and interpreted 
data, and wrote the manuscript; AC designed and performed 
experiments and analyzed and interpreted data; K-JC designed 
experiments and interpreted data; MP performed experiments; 
DV provided essential experimental tools; AR co-designed the 
project, analyzed and interpreted data, and edited the manuscript; 
and TC co-designed the project and wrote the manuscript.
acKnOWleDgMenTs
The authors thank Bettina Gercken and Christina Hiller for 
technical assistance.
FUnDing
This work was supported by the German Research Foundation 
(grants CH279/5-1 to TC and RO2133/7-1 to AR) and Czech 
Academy of Sciences (grant 16-07117Y to JC).
reFerences
1. Mcnelis JC, Olefsky JM. Macrophages, immunity, and metabolic disease. 
Immunity (2014) 41:36–48. doi:10.1016/j.immuni.2014.05.010 
2. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. Cell 
(2014) 156:20–44. doi:10.1016/j.cell.2013.12.012 
3. Seijkens T, Kusters P, Chatzigeorgiou A, Chavakis T, Lutgens E. Immune cell 
crosstalk in obesity: a key role for costimulation? Diabetes (2014) 63:3982–91. 
doi:10.2337/db14-0272 
4. Chmelar J, Chung KJ, Chavakis T. The role of innate immune cells in obese 
adipose tissue inflammation and development of insulin resistance. Thromb 
Haemost (2013) 109:399–406. doi:10.1160/TH12-09-0703 
5. Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev 
Immunol (2011) 29:415–45. doi:10.1146/annurev-immunol-031210-101322 
6. Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med (2012) 
18:693–704. doi:10.1038/nm.2755 
7. Yu Y, Blokhuis BR, Garssen J, Redegeld FA. Non-IgE mediated mast cell acti-
vation. Eur J Pharmacol (2016) 778:33–43. doi:10.1016/j.ejphar.2015.07.017 
8. Marshall JS. Mast-cell responses to pathogens. Nat Rev Immunol (2004) 
4:787–99. doi:10.1038/nri1460 
9. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune 
responses. Nat Immunol (2005) 6:135–42. doi:10.1038/ni1158 
10. Abraham SN, St John AL. Mast cell-orchestrated immunity to pathogens. Nat 
Rev Immunol (2010) 10:440–52. doi:10.1038/nri2782 
11. Rodewald HR, Feyerabend TB. Widespread immunological functions 
of mast cells: fact or fiction? Immunity (2012) 37:13–24. doi:10.1016/ 
j.immuni.2012.07.007 
12. Liu J, Divoux A, Sun J, Zhang J, Clement K, Glickman JN, et al. Genetic defi-
ciency and pharmacological stabilization of mast cells reduce diet-induced 
obesity and diabetes in mice. Nat Med (2009) 15:940–5. doi:10.1038/nm.1994 
13. Tanaka A, Nomura Y, Matsuda A, Ohmori K, Matsuda H. Mast cells 
function as an alternative modulator of adipogenesis through 15-deoxy-
delta-12, 14-prostaglandin J2. Am J Physiol Cell Physiol (2011) 301:C1360–7. 
doi:10.1152/ajpcell.00514.2010 
14. Altintas MM, Nayer B, Walford EC, Johnson KB, Gaidosh G, Reiser J, 
et  al. Leptin deficiency-induced obesity affects the density of mast cells in 
abdominal fat depots and lymph nodes in mice. Lipids Health Dis (2012) 11:21. 
doi:10.1186/1476-511X-11-21 
15. Divoux A, Moutel S, Poitou C, Lacasa D, Veyrie N, Aissat A, et al. Mast cells 
in human adipose tissue: link with morbid obesity, inflammatory status, 
8Chmelarˇ et al.
Frontiers in Immunology | www.frontiersin.org November 2016 | Volume 7 | Article 524
No Role for Mast Cells in Obesity
and diabetes. J Clin Endocrinol Metab (2012) 97:E1677–85. doi:10.1210/
jc.2012-1532 
16. Gutierrez DA, Muralidhar S, Feyerabend TB, Herzig S, Rodewald HR. 
Hematopoietic kit deficiency, rather than lack of mast cells, protects mice 
from obesity and insulin resistance. Cell Metab (2015) 21:678–91. doi:10.1016/ 
j.cmet.2015.04.013 
17. Feyerabend TB, Weiser A, Tietz A, Stassen M, Harris N, Kopf M, et  al. 
Cre-mediated cell ablation contests mast cell contribution in models of 
antibody- and T cell-mediated autoimmunity. Immunity (2011) 35:832–44. 
doi:10.1016/j.immuni.2011.09.015 
18. Zhou Y, Yu X, Chen H, Sjoberg S, Roux J, Zhang L, et al. Leptin deficiency shifts 
mast cells toward anti-inflammatory actions and protects mice from obesity 
and diabetes by polarizing M2 macrophages. Cell Metab (2015) 22:1045–58. 
doi:10.1016/j.cmet.2015.09.013 
19. Scholten J, Hartmann K, Gerbaulet A, Krieg T, Muller W, Testa G, et al. Mast 
cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res (2008) 
17:307–15. doi:10.1007/s11248-007-9153-4 
20. Dudeck A, Dudeck J, Scholten J, Petzold A, Surianarayanan S, Kohler A, et al. 
Mast cells are key promoters of contact allergy that mediate the adjuvant effects 
of haptens. Immunity (2011) 34:973–84. doi:10.1016/j.immuni.2011.03.028 
21. Chatzigeorgiou A, Seijkens T, Zarzycka B, Engel D, Poggi M, Van Den 
Berg S, et  al. Blocking CD40-TRAF6 signaling is a therapeutic target in 
 obesity-associated insulin resistance (vol 111, pg 2686, 2014). Proc Natl Acad 
Sci U S A (2014) 111:4644–4644. doi:10.1073/pnas.1400419111 
22. Garcia-Martin R, Alexaki VI, Qin N, Rubin, De Celis MF, Economopoulou M, 
et  al. Adipocyte-specific hypoxia-inducible factor 2alpha deficiency 
exacerbates obesity-induced brown adipose tissue dysfunction and 
metabolic dysregulation. Mol Cell Biol (2016) 36:376–93. doi:10.1128/ 
MCB.00430-15 
23. Phieler J, Chung KJ, Chatzigeorgiou A, Klotzsche-Von Ameln A, Garcia-
Martin R, Sprott D, et  al. The complement anaphylatoxin C5a receptor 
contributes to obese adipose tissue inflammation and insulin resistance. 
J Immunol (2013) 191:4367–74. doi:10.4049/jimmunol.1300038 
24. Chatzigeorgiou A, Chung KJ, Garcia-Martin R, Alexaki VI, Klotzsche-Von 
Ameln A, Phieler J, et  al. Dual role of B7 costimulation in obesity-related 
nonalcoholic steatohepatitis and metabolic dysregulation. Hepatology (2014) 
60:1196–210. doi:10.1002/hep.27233 
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (2001) 
25:402–8. doi:10.1006/meth.2001.1262 
26. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, 
et al. Design and validation of a histological scoring system for nonalcoholic 
fatty liver disease. Hepatology (2005) 41:1313–21. doi:10.1002/hep.20701 
27. Voehringer D, Liang HE, Locksley RM. Homeostasis and effector function of 
lymphopenia-induced “memory-like” T cells in constitutively T cell-depleted 
mice. J Immunol (2008) 180:4742–53. doi:10.4049/jimmunol.180.7.4742
28. Peschke K, Weitzmann A, Heger K, Behrendt R, Schubert N, Scholten J, et al. 
IkappaB kinase 2 is essential for IgE-induced mast cell de novo cytokine 
production but not for degranulation. Cell Rep (2014) 8:1300–7. doi:10.1016/ 
j.celrep.2014.07.046 
29. Altintas MM, Azad A, Nayer B, Contreras G, Zaias J, Faul C, et al. Mast cells, 
macrophages, and crown-like structures distinguish subcutaneous from 
visceral fat in mice. J Lipid Res (2011) 52:480–8. doi:10.1194/jlr.M011338 
30. Altintas MM, Rossetti MA, Nayer B, Puig A, Zagallo P, Ortega LM, et  al. 
Apoptosis, mastocytosis, and diminished adipocytokine gene expression 
accompany reduced epididymal fat mass in long-standing diet-induced obese 
mice. Lipids Health Dis (2011) 10:198. doi:10.1186/1476-511X-10-198 
31. Otsuka A, Kubo M, Honda T, Egawa G, Nakajima S, Tanizaki H, et  al. 
Requirement of interaction between mast cells and skin dendritic cells to 
establish contact hypersensitivity. PLoS One (2011) 6:e25538. doi:10.1371/
journal.pone.0025538 
32. Antsiferova M, Martin C, Huber M, Feyerabend TB, Forster A, Hartmann K, 
et  al. Mast cells are dispensable for normal and activin-promoted wound 
healing and skin carcinogenesis. J Immunol (2013) 191:6147–55. doi:10.4049/
jimmunol.1301350 
33. Gomez-Pinilla PJ, Farro G, Di Giovangiulio M, Stakenborg N, Nemethova A, 
De Vries A, et  al. Mast cells play no role in the pathogenesis of postoper-
ative ileus induced by intestinal manipulation. PLoS One (2014) 9:e85304. 
doi:10.1371/journal.pone.0085304 
34. Gutierrez DA, Fu W, Schonefeldt S, Feyerabend TB, Ortiz-Lopez A, Lampi Y, 
et al. Type 1 diabetes in NOD mice unaffected by mast cell deficiency. Diabetes 
(2014) 63:3827–34. doi:10.2337/db14-0372 
35. Schonhuber N, Seidler B, Schuck K, Veltkamp C, Schachtler C, Zukowska M, 
et al. A next-generation dual-recombinase system for time- and host-specific 
targeting of pancreatic cancer. Nat Med (2014) 20:1340–7. doi:10.1038/
nm.3646 
36. Willenborg S, Eckes B, Brinckmann J, Krieg T, Waisman A, Hartmann K, 
et  al. Genetic ablation of mast cells redefines the role of mast cells in skin 
wound healing and bleomycin-induced fibrosis. J Invest Dermatol (2014) 
134:2005–15. doi:10.1038/jid.2014.12 
37. Paul C, Wolff S, Zapf T, Raifer H, Feyerabend TB, Bollig N, et al. Mast cells 
have no impact on cutaneous leishmaniasis severity and related Th2 differ-
entiation in resistant and susceptible mice. Eur J Immunol (2016) 46:114–21. 
doi:10.1002/eji.201545613 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The reviewer AF and handling Editor declared their shared affiliation, and the 
handling Editor states that the process nevertheless met the standards of a fair and 
objective review.
Copyright © 2016 Chmelař, Chatzigeorgiou, Chung, Prucnal, Voehringer, Roers and 
Chavakis. This is an open-access article distributed under the terms of the Creative 
Commons Attribution License (CC BY). The use, distribution or reproduction in 
other forums is permitted, provided the original author(s) or licensor are credited 
and that the original publication in this journal is cited, in accordance with accepted 
academic practice. No use, distribution or reproduction is permitted which does not 
comply with these terms.
